Platforms

The integration of genome mining, protein engineering and automated functional testing creates a highly efficient development environment for optogenetic actuators. The systematically collected data provides valuable insights into the opsin fitness landscape and opens up new avenues for data-driven and structure-based protein design - for more precise, more effective therapies of tomorrow.

To develop precise and safe optogenetic treatments, we design adeno-associated viral vectors (rAAV) that are precisely tailored to the requirements of the target cells. Through screening, optimization and targeted combination of capsid variants, we improve specificity, efficiency and biological safety profile. Building on this foundation, we create a scalable, GMP-compliant production process for clinical applications - supported by the expertise of leading research laboratories.

Using human organoids, animal models and computer-aided simulations, we develop robust preclinical models to evaluate the safety and efficacy of optogenetic therapies. In silico, we test targeted stimulation paradigms to restore neuronal functions - faster and more animal-friendly. In vitro, we validate vector strategies in human organoids before testing promising approaches in vivo in different species. The close integration of these systems provides a deep, integrated understanding of the mechanism of action and the targeted development of optogenetic treatments.

To ensure the tolerability of optogenetic therapies, we systematically analyze tissue changes, immune cell infiltrations and cellular and humoral immune responses after gene transfer. Through histological, serological and cellular examinations, we identify possible immunological triggers and develop strategies to minimize unwanted reactions. The close collaboration of immunological, neuropathological and physiological expertise creates the basis for safe and well-tolerated therapy concepts.

We develop miniaturized, durable medical devices with maximum light output for targeted optogenetic stimulation. A flexible system of energy and data coupling, integrated control and light conduction enables the precise stimulation of distant target regions. Prototypes for clinical use - robust, adaptable and application-oriented - are developed in close cooperation with industrial partners. The first milestone: a functional design stop for optical cochlear implants by 2028.